Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bumetanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.92 |
| ▸ | USP2 | O75604 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.92 |
| ▸ | HPGD | P15428 | 2/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.92 |
| ▸ | CA2 | P00918 | 1/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.92 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.92 |
| ▸ | AQP1 | P29972 | 1/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bumetanide SCHEMBL4425232 | 0.96 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL29388271 | 0.96 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL27525 | 0.96 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL6239781 | 0.95 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL251062 | 0.95 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL23455698 | 0.95 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL28661289 | 0.95 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL2255359 | 0.95 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL250621 | 0.94 | KDM4E (0.96) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL28549675 | 0.94 | KDM4E (0.96) | KDM4EUSP2ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082187-A1 | PHARMACEUTICAL COMPOSITION | NEUROPRO THERAPEUTICS, INC. | 2024-03-14 | — | — | US | claimed |
| WO-2024039653-A1 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | NEUROPRO THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| US-20230293469-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | NEUROPRO THERAPEUTICS, INC. | 2023-09-21 | — | — | US | claimed |
| WO-2023129649-A1 | PHARMACEUTICAL COMPOSITION | NEUROPRO THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | claimed |
| EP-4175626-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | NEUROPRO THERAPEUTICS, INC. (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2022006392-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | NEUROPRO THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | claimed |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2021-05-13 | — | — | US | claimed |
| EP-2790686-B1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Zilentin AG (CH) | 2021-03-10 | — | — | EP | claimed |
| EP-2919769-B1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING FRAGILE X SYNDROME | NEUROCHLORE (FR) | 2020-09-09 | — | — | EP | claimed |
| US-10709682-B2 | Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system | OTOLANUM AG (CH) | 2020-07-14 | — | — | US | claimed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | claimed |
| EP-1874286-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1874286-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | Neurotherapeutics Pharma LLC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | claimed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | SLC1A2, SLC18A2, GRIN2C | KDM4E 1867/4885USP2 2928/4885ALDH1A1 1109/4885 |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A13, SLC6A11 | KDM4E 3327/4885USP2 3557/4885ALDH1A1 1240/4885 |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | AQP4, AVPR2, AQP1 | KDM4E 3557/4885USP2 3459/4885ALDH1A1 687/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | KDM4E 1504/4885USP2 3752/4885ALDH1A1 701/4885 |
| US-10709682-B2 | Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system | SLC6A1, SLC6A11, SLC6A13 | KDM4E 3378/4885USP2 3653/4885ALDH1A1 1220/4885 |
| US-20230293469-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | ABCG2, SLC18A1, CFTR | KDM4E 1496/4885USP2 1809/4885ALDH1A1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.